BackSecond Sight Medical Products Overview

Second Sight Medical Products Accounts Payable

Latest accounts payable for EYES: $1.2M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$1.20M
↓ 32.18% YoYΔ $-567000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Second Sight Medical Products Accounts Payable History

Loading

Second Sight Medical Products vs. peers: Accounts Payable Comparison

Loading

Second Sight Medical Products Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Second Sight Medical Products (EYES) FAQ

Second Sight Medical Products's accounts payable stands at $1.2M as of June 2026. That compares with $1.8M in the prior-year period — down 32.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Second Sight Medical Products reported $1.2M in accounts payable versus $1.8M a year earlier — a 32.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.8M in the prior-year period — down 32.2% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Second Sight Medical Products's accounts payable evolved across reporting periods, while the comparison chart places EYES next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Second Sight Medical Products's reading of $1.2M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.